# Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

> **NCT01550224** · PHASE2 · COMPLETED · sponsor: **Steven E. Coutre** · enrollment: 23 (actual)

## Conditions studied

- Acute Myeloid Leukemia With 11q23-abnormality in Relapse

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01550224
- **Lead sponsor:** Steven E. Coutre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-01
- **Primary completion:** 2014-11-17
- **Final completion:** 2014-11-17
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01550224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01550224, "Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01550224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*